Moderna, Inc. (NASDAQ:MRNAGet Rating) – Equities researchers at SVB Leerink cut their Q3 2022 earnings per share estimates for shares of Moderna in a report released on Thursday, August 4th. SVB Leerink analyst M. Foroohar now forecasts that the company will earn $5.45 per share for the quarter, down from their prior estimate of $5.68. SVB Leerink has a “Underperform” rating and a $77.00 price objective on the stock. The consensus estimate for Moderna's current full-year earnings is $27.29 per share. SVB Leerink also issued estimates for Moderna's FY2023 earnings at $7.83 EPS and FY2024 earnings at $4.05 EPS.

Other research analysts also recently issued research reports about the stock. Piper Sandler dropped their price objective on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. Morgan Stanley dropped their price objective on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating for the company in a report on Thursday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $226.92.

Moderna Trading Up 4.1 %

Shares of MRNA stock opened at $194.18 on Friday. The stock has a fifty day simple moving average of $151.55 and a two-hundred day simple moving average of $152.84. Moderna has a 52-week low of $115.61 and a 52-week high of $497.49. The firm has a market capitalization of $77.24 billion, a PE ratio of 5.92, a PEG ratio of 1.05 and a beta of 1.61. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.99.

Ad Investing Trends

Copper Exploration Heating Up

Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $5.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.73 by $0.51. Moderna had a return on equity of 94.76% and a net margin of 61.12%. The business had revenue of $4.73 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the prior year, the business posted $6.46 EPS. Moderna's revenue for the quarter was up 8.7% compared to the same quarter last year.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 10,000 shares of Moderna stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $123.00, for a total transaction of $1,230,000.00. Following the transaction, the president now directly owns 1,624,231 shares of the company's stock, valued at $199,780,413. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Moderna news, President Stephen Hoge sold 10,000 shares of Moderna stock in a transaction on Monday, June 13th. The shares were sold at an average price of $123.00, for a total value of $1,230,000.00. Following the transaction, the president now directly owns 1,624,231 shares of the company's stock, valued at $199,780,413. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $156.73, for a total transaction of $6,269,200.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $848,214,296.58. The disclosure for this sale can be found here. Over the last three months, insiders have sold 554,029 shares of company stock valued at $82,263,545. 17.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently made changes to their positions in MRNA. Confluence Wealth Services Inc. acquired a new stake in shares of Moderna during the fourth quarter worth $25,000. Standard Family Office LLC acquired a new position in Moderna during the fourth quarter valued at $25,000. Total Clarity Wealth Management Inc. acquired a new position in Moderna during the second quarter valued at $25,000. AllSquare Wealth Management LLC acquired a new position in Moderna during the first quarter valued at $26,000. Finally, IFS Advisors LLC acquired a new position in Moderna during the fourth quarter valued at $27,000. 61.20% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Cap Expand Partners EarningsEstimatesChart Q3 2022 Earnings Estimate for Moderna, Inc. (NASDAQ:MRNA) Issued By SVB Leerink Family Offices AND investments

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Moderna right now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Moderna wasn't on the list.

While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Cap Expand Partners sharing news from: www.marketbeat.com

Share: